Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 16:02 ET | Source: Ardelyx, Inc.

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
March 31, 2025 16:03 ET | Source: Ardelyx, Inc.

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
March 13, 2025 08:02 ET | Source: Ardelyx, Inc.

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
February 26, 2025 07:00 ET | Source: Ardelyx, Inc.

Tenapanor Approved in China for Hyperphosphatemia

WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
February 25, 2025 16:15 ET | Source: Ardelyx, Inc.

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
February 20, 2025 07:30 ET | Source: Ardelyx, Inc.

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of...
February 19, 2025 08:01 ET | Source: Ardelyx, Inc.

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
January 30, 2025 16:30 ET | Source: Ardelyx, Inc.

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
January 13, 2025 08:03 ET | Source: Ardelyx, Inc.

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales...
January 06, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...